iTeos Therapeutics Stock (NASDAQ:ITOS)
Previous Close
$7.22
52W Range
$7.09 - $18.75
50D Avg
$8.60
200D Avg
$12.81
Market Cap
$271.08M
Avg Vol (3M)
$564.86K
Beta
1.39
Div Yield
-
ITOS Company Profile
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
ITOS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SANA | Sana Biotechnology, Inc. |
| RVMD | Revolution Medicines, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| BPMC | Blueprint Medicines Corporation |
| DAWN | Day One Biopharmaceuticals, Inc. |
| ERAS | Erasca, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| TCRX | TScan Therapeutics, Inc. |
| ANNX | Annexon, Inc. |
| MLTX | MoonLake Immunotherapeutics |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |